Search Results

Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform

Glycotope GmbH has signed an agreement with Evotec SE to combine Glycotope’s antibodies with Evotec’s immune cell engager platform for the development of next generation immune cell engaging bispecifics by Evotec.

December 11, 2023

·

3 min read

Business

Pentixapharm Acquires Target Discovery Business of Glycotope

July 3, 2024

·

4 min read

LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody Drug Conjugate Development

LegoChem Biosciences Inc. and Glycotope GmbH have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational antibodies, building on a previously announced 2022 collaboration and license agreement.

October 16, 2023

·

3 min read

Glycotope and Max Delbrück Center enter into research collaboration to explore combination of GlycoTargets and CAR technology

Glycotope GmbH and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes with chimeric antigen receptor technology developed by the Max Delbrück Center.

September 25, 2023

·

5 min read

Glycotope Presents anti-GlycoTarget Antibodies at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting

Glycotope GmbH announces that it will present a poster on antibodies that specifically recognize cancer-associated glycoforms of mucin-like proteins at the 2023 Society for Immunotherapy of Cancer Meeting, being held in San Diego, California, United States, between 1-5 November 2023.

November 3, 2023

·

2 min read

Biotech Beach

Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer

Therabest USA. Inc, Therabest Korea and Glycotope GmbH have signed an agreement to assess the clinical development of Therabest’s EiNKTM cell therapy, TB-100, in combination with Glycotope’s immuno-cytokine, GT-00AxIL15 in triple-negative breast cancer patients.

December 13, 2022

·

4 min read

Glycotope Presents Glyco-Engineered Cell Lines at the 2023 American Association for Cancer Research (AACR) Meeting

Glycotope GmbH announces that it will present its glyco-engineered cell lines in a poster presentation at the 2022 American Association for Cancer Research Meeting, being held in Orlando, Florida, United States, between 14-19 April 2023.

April 17, 2023

·

1 min read

LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate

LegoChem Biosciences Inc. and Glycotope GmbH have signed a Research Collaboration and License Agreement to develop an antibody drug conjugate by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational tumor targeting antibodies.

July 12, 2022

·

3 min read

Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH

Glycotope GmbH and CantonBio Deutschland GmbH announced the successful completion of CantonBio’s acquisition of Glycotope’s service business under the newly formed FyoniBio GmbH.

February 1, 2022

·

4 min read

Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting

Glycotope GmbH announces that it will present new data at the 2022 Society for Immunotherapy of Cancer Annual Meeting, being held in Boston, United States, between 8-12 November 2022.

November 8, 2022

·

2 min read